Business Description
4d pharma PLC
ISIN : US35085K1170
Share Class Description:
LBPWQ: Warrants (22/02/2025)Total Employee Number:
88Description
4d pharma PLC and its subsidiaries are in the business of research and development and production of live biotherapeutic products. The company develops biotherapeutic products for diseases such as cancer, asthma, autism, and autoimmune conditions such as arthritis and multiple sclerosis. Its developing science includes Live biotherapeutics, Microbiome, MicroRx, MicroDx, and others.
Financial Strength
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 1.56 | |||||
Equity-to-Asset | 0.54 | |||||
Debt-to-Equity | 0.43 | |||||
Debt-to-EBITDA | -0.18 | |||||
Piotroski F-Score | 2/9 | |||||
Altman Z-Score | -8.3 | |||||
Beneish M-Score | -5.97 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 4 | |||||
3-Year EPS without NRI Growth Rate | 6.9 | |||||
3-Year FCF Growth Rate | 26.3 | |||||
3-Year Book Growth Rate | -43.1 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 5.21 | |||||
Quick Ratio | 5.16 | |||||
Cash Ratio | 3.17 | |||||
Days Sales Outstanding | 1799.48 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -40.2 | |||||
Shareholder Yield % | -25.14 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Operating Margin % | -5082.18 | |||||
Net Margin % | -10337.16 | |||||
EBITDA Margin % | -10704.79 | |||||
ROE % | -204.06 | |||||
ROA % | -128.47 | |||||
ROIC % | -108.4 | |||||
3-Year ROIIC % | 336.49 | |||||
ROC (Joel Greenblatt) % | -820.34 | |||||
ROCE % | -158.47 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | N/A |
N/A
|
N/A
| |||
PE Ratio without NRI | N/A |
N/A
|
N/A
| |||
EV-to-FCF | -0.97 | |||||
FCF Yield % | -3580900 |
GF Value™
4d pharma PLC Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
4d pharma PLC Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Second quarter earnings results for 2026 | 2026-08-14 | 0.00 (+0.00%) | ||
| Annual report for 2025 | 2026-04-20 | 0.00 (+0.00%) | ||
| Fourth quarter earnings results for 2025 | 2026-03-16 | 0.00 (+0.00%) | ||
| General meeting for 2024 | 2026-02-26 | 0.00 (+0.00%) |
Show
Entries
Press Release
Articles on 4d pharma PLC
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers